IBJNews

Deal could give Lilly full diabetes deck

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.'s diabetes partnership with German company Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.

Indianapolis-based Lilly traditionally has been strong in injectable medicines to help diabetics control their blood glucose—insulins taken at mealtime and Byetta, which inhibits proteins similar to glucose and requires twice-daily injections.

But Lilly has stumbled in developing more convenient diabetes medicines, such as the once-daily insulin Lantus or oral diabetes pills like Januvia.

That has led the company to lose quite a bit of worldwide market share in the past decade, even though the growing incidence of diabetes has kept its overall diabetes sales growing.

Lilly’s suite of diabetes products is currently racking up about $3.8 billion in annual sales, up a total of 17 percent in the past three years.

Lilly’s $1.2 billion deal with Boehringer would give it 50-percent rights to two oral diabetes medicines that are in late stages of development. Boehringer’s linagliptin already has completed clinical trials and is expected to receive approval to launch in the United States, Europe and Japan this year. The other drug, known as BI10773, is in Phase 3 clinical trials, the last step before regulatory submission.

In addition, Lilly has two daily insulins in development, for which it will now get some help from Boehringer—both in bearing the cost of further development and, should they win approval, promoting them to doctors. They could hit the market as soon as 2014, and Boehringer would pay up to $650 million to Lilly as they reach key developmental milestones.

If the companies can get at least one oral diabetes pill and one daily insulin onto the market, Lilly will be able to boast the broadest portfolio of diabetes drugs, ranging from the oral medicines patients take in the early stages of diabetes to the types of insulins they take as the disease worsens.

“You’ve got 300 million people worldwide with diabetes and the disease burden is growing,” said Lilly CEO John Lechleiter. “Many of those are going to move on and progress in their treatment from oral medications to insulin.”

Providing medicines—as well as helpful education materials and other services—could be a way to win patient loyalty, and therefore boost sales, according to Deloitte consultant Terri Cooper.

In a 2008 report, she predicted that pharmaceutical companies will form themselves around specific diseases and tailor medicines to smaller groups of patients that respond to medicines in common ways because they share genetic traits.

“There will be a lot more focus around disease states, rather than the therapeutic areas,” she said in an interview the following year.

Later that year, Lilly reorganized itself into distinct business units, with one of them solely focused on diabetes. And on Tuesday, Lilly’s president of diabetes, Enrique Conterno, predicted that by beefing up its diabetes portfolio overall, the company would see higher sales of some of its existing diabetes medicines.

“What this alliance I think provides is the critical mass that we have of all of these products,” he said. “This alliance is highly complementary and highly strategic for us.”

Wall Street analysts tended to agree, even if they don’t see the deal doing that much to fix Lilly’s looming patent challenges. The company will see five of its bestsellers face generic competition by the end of 2013, sapping roughly half its revenue.

“This deal should inject some life into [Lilly's] diabetes franchise, which has been losing share, given the broad range of products they should eventually be able to offer,” Credit Suisse analyst Catherine Arnold wrote in a note to investors.

ADVERTISEMENT

  • Father creates system to manage daughter's diabetes
    My daughter has been a diabetic for 10 years and I have always been frustrated with the tools to manage her diabetes so with help from other patients and Riley Hospital for Children I created a toolset that combines Clinical, Social, Behavioral, and Financial into one platform from a patientâ??s perspective. We have reduced my daughterâ??s A1C level by 1.5 points by using the system.

    This toolset can be accessed from a new website I developed to make managing chronic disease easy for patients. The system accept data from all medical devices and create easy to read dashboards and reports for patients. Patients and caregivers can now have access to daily biometric data on a near real-time bases instead of having to wait for claims or lab data. We have social media built into the platform for collaboration between patients and caregivers, and a rewards program for compliancy. Think about this as iPod meets Facebook with rewards for compliance for healthcare.


    Anyone can also test drive the tools at https://demo.s5health.com.
    Founder
    s5health
    www.s5health.com

  • Big business
    Lilly has been part of my life ever since I was diagnosed as a juvenile diabetic at age 10. (Now known as Type 1) While I am so thankful to have had a medicine,insulin, that saved my life, I am beginning to think diabetes is such a big business for Lilly and many other companies that there will never be a cure. It would put too many people out of work. My hope remains in the promise at Revelation 21:4 and Isaiah 33:24.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT